SCOPE Project Reaches Out to Minorities
PITTSBURGH-The National Surgical Adjuvant Breast and Bowel Project (NSABP) is encouraging women from racial and ethnic minority groups to consider joining the group’s Study of Tamoxifen and Raloxifene (STAR).
PITTSBURGHThe National Surgical Adjuvant Breast and Bowel Project (NSABP) is encouraging women from racial and ethnic minority groups to consider joining the groups Study of Tamoxifen and Raloxifene (STAR).
The study will compare the proven benefits of tamoxifen (Nolvadex) in reducing the incidence of breast cancer in healthy high-risk women against the promising effects of raloxifene (Evista), which is FDA approved to prevent and treat osteoporosis in postmenopausal women. Over a 5-year period, STAR will enroll 22,000 women. As of March 31, 2000, 4,598 women had joined and 4% are from a racial or ethnic minority group.
The NSABP has a special educational effort underway, SCOPEthe STAR Community Outreach Program for Educationto address myths in the minority community about breast cancer and to encourage more minority women to participate in clinical trials.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.
